Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
59th Medical Wing
With
U.S. Air Force Office of the Surgeon General
Emergency Medicine Foundation
All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1) septa double strength two pills orally twice a day x 7 days or 2)placebo. Patients will then return to the emergency room on days 3 and 7 for wound repacking and evaluation. The primary outcome recurrence rates within 30 days of treatment. Patients who are not improving at the following visit will then be treated with additional antibiotics if needed. Data will be analyzed both by initial randomization and intention to treat.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
All patients age 18-65 who present to the emergency department with a skin abscess that requires incision and drainage.
You may not be if
Patients with diabetes, HIV, cancer or other immunocompromised patients.
Additionally, any patients who received antibiotics within one week of presentation or were hospitalized in previous month will be excluded to minimize potential confounding variables.
Pregnant and breastfeeding patients will also be excluded due to possible safety concerns with antibiotic treatment.
Patients with abscesses on head, face, perirectal, or periananal regions, abscesses with known tracks or fistulas to deeper structures, or abscesses requiring surgical drainage in an operating room are excluded.
Finally, patients with sulfa allergy will be excluded.